Introduction: In recent years, the development of artificial intelligence (AI) technologies, including machine learning, deep learning, and large language models, has significantly supported clinical work. Concurrently, the integration of artificial intelligence with the medical field has garnered increasing attention from medical experts. This study undertakes a dynamic and longitudinal bibliometric analysis of AI publications within the healthcare sector over the past three decades to investigate the current status and trends of the fusion between medicine and artificial intelligence.Methods: Following a search on the Web of Science, researchers retrieved all reviews and original articles concerning artificial intelligence in healthcare published between January 1993 and December 2023. The analysis employed Bibliometrix, Biblioshiny, and Microsoft Excel, incorporating the bibliometrix R package for data mining and analysis, and visualized the observed trends in bibliometrics.Results: A total of 22,950 documents were collected in this study. From 1993 to 2023, there was a discernible upward trajectory in scientific output within bibliometrics. The United States and China emerged as primary contributors to medical artificial intelligence research, with Harvard University leading in publication volume among institutions. Notably, the rapid expansion of emerging topics such as COVID-19 and new drug discovery in recent years is noteworthy. Furthermore, the top five most cited papers in 2023 were all pertinent to the theme of ChatGPT.Conclusion: This study reveals a sustained explosive growth trend in AI technologies within the healthcare sector in recent years, with increasingly profound applications in medicine. Additionally, medical artificial intelligence research is dynamically evolving with the advent of new technologies. Moving forward, concerted efforts to bolster international collaboration and enhance comprehension and utilization of AI technologies are imperative for fostering novel innovations in healthcare.
Lipid disturbance induced by high-fat diet is a worldwide problem, and it can induce inflammation and oxidative stress in vivo. Zinc is considered as an antioxidant, anti-inflammatory agent. Since matrix metalloprotease 2 (MMP2) and matrix metalloprotease 9 (MMP9)’s expressions are changed under many pathological conditions, we would like to know how zinc affects lipid metabolism and MMP2, MMP9’s expressions in the lipid disturbance rabbits. Twenty-four male New Zealand white rabbits were randomly divided into four groups. Each group had six rabbits, and they were fed with regular diet, high-fat diet, high-fat diet + zinc, and regular diet + zinc separately for 12 weeks. High-fat diet induced lipid disturbance significantly which raised the level of aspartate aminotransferase (p < 0.01) and alanine transaminase (p < 0.05) in the high-fat diet group, but zinc supplement reversed this phenomenon (p < 0.05). Zinc did not reduce total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) (p > 0.05), but it lowered triglyceride (TG) and raised high-density lipoprotein cholesterol (HDL-C) (p < 0.01). Zinc also reduced high-sensitivity C-reactive protein (hs-CRP) (p < 0.01) and interleukin-6 (IL-6)’s expressions (p < 0.05). Zinc reduced the epicardial adipose tissue and alleviated the hepatic steatosis. Zinc suppressed MMP2 and MMP9’s expressions in vivo, but it did not alleviate the aorta fatty streak’s severity in the lipid disturbance rabbits. Zinc protected the liver, reduced TG, hs-CRP, and IL-6 and raised HDL-C in the lipid disturbance rabbits. Zinc suppressed MMP2 and MMP9’s expressions in vivo, but it did not alleviate the severity of aorta fatty streak induced by the high-fat diet.
1 January 2013 in Biochemical and Biophysical Research Communications
Summary: Aims: Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)‐β/Smad signaling pathway, improves cardiac function and reduces fibrosis. We determined whether these effects were common among the diuretics and whether angiotensin II receptor type 1 (AT1) signaling pathway played a role in these effects.Methods: Heart failure was produced by ligating the left anterior descending coronary artery in adult male Sprague Dawley rats. Two weeks after the ligation, 70 rats were randomly divided into five groups: sham‐operated group, control group, valsartan group (80 mg/kg/d), hydrochlorothiazide group (12.5 mg/kg/d) and furosemide group (20 mg/kg/d). In addition, neonatal rat ventricular fibroblasts were treated with angiotensin II.Results: After eight‐week drug treatment, hydrochlorothiazide group and valsartan group but not furosemide group had improved cardiac function (ejection fraction was 49.4±2.1%, 49.5±1.8% and 39.9±1.9%, respectively, compared with 40.1±2.2% in control group), reduced cardiac interstitial fibrosis and collagen volume fraction (9.7±1.2%, 10.0±1.3% and 14.1±0.8%, respectively, compared with 15.9±1.1% in control group), and decreased expression of AT1, TGF‐β and Smad2 in the cardiac tissues. In addition, hydrochlorothiazide reduced plasma angiotensin II and aldosterone levels. Furthermore, hydrochlorothiazide inhibited angiotensin II‐induced TGF‐β1 and Smad2 protein expression in the neonatal rat ventricular fibroblasts.Conclusions: Our study indicates that the cardiac function and remodeling improvement after ischemic heart failure may not be common among the diuretics. Hydrochlorothiazide may reduce the left ventricular wall stress and angiotensin II signaling pathway to provide these beneficial effects.
Although fibronectin has been associated with the pathogenesis of atherosclerosis, little is currently known about the relationship between plasma fibronectin and coronary heart disease (CHD). This retrospective study aimed to determine the predictive value of plasma fibronectin for CHD and its severity. A total of 1644 consecutive patients who underwent selective coronary angiography were recruited into the present study. The characteristics and results of the clinical examination of all patients were collected. Logistic regression analyses were performed to determine the predictive value of plasma fibronectin for the presence and severity of CHD. Compared with non-CHD patients, the CHD patients showed significantly higher plasma levels of troponin I and creatine kinase isoenzyme, along with lower plasma levels of fibronectin. However, no significant differences were detected in plasma fibronectin among patients with different grades of CHD. The logistic regression model showed that plasma fibronectin remained an independent predictor of CHD after adjustment with a 1.39-fold increased risk for every 1 SD decrease in plasma fibronectin. Nevertheless, plasma fibronectin could not predict the severity of CHD determined by the number of stenosed vessels and the modified Gensini score. This study demonstrated that lower plasma fibronectin might be an independent predictor of CHD, but it may be of no value in predicting the severity of CHD.